...
首页> 外文期刊>Sarcoma >Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation
【24h】

Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation

机译:免疫组织化学估计的血管生成,增殖活性,p53表达和多重耐药对骨肉瘤没有预后影响:比较临床病理研究。

获取原文
           

摘要

Purpose. To investigate angiogenesis, multiple drug resistance (MDR) and proliferative activity as prognostic variables in patients suffering from osteosarcoma.Methods. Histologic biopsies from 117 patients treated in the period from 1972 through 1999 were immunohistologically investigated regarding angiogenesis (CD34), proliferative activity (MIB-1), and the expression of p53 and MDR (P-glycoprotein (Pgp); clones JSB-1, C494, and MRK16). Quantitative and semiquantitative scores of immunoreactive cells were analyzed statistically along with retrospectively obtained clinicopathologic variables.Results. Chemotherapy reduced the rate of amputations (P=.00002). The Pgp was overexpressed (score ≥2) in 48% of the primary, diagnostic biopsies, and high Pgp correlated with high Pgp in postsurgical specimens (P=.003). In contrast, no such associations were disclosed for estimates of angiogenesis (P=.64) and p53 (P>.32), whereas the MIB-1 index was reduced in the post-chemotherapy specimens (P=.02).The overall, disease-specific survival was 47%, increasing to 54% in patients receiving pre-operative chemotherapy. Statistical analyses showed prognostic impact exclusively by patient age and type of osteosarcoma.Discussion. The studied series of patients documented already prior to the chemotherapy era, a rather excellent survival and estimates of angiogenesis, proliferation, p53, and Pgp expressions, did not demonstrate sufficient power to serve as predictors of treatment response or survival.
机译:目的。目的探讨骨肉瘤患者的血管生成,多重耐药(MDR)和增殖活性作为预后变量。对1972年至1999年期间接受治疗的117例患者的组织学活检进行了免疫组织学研究,涉及血管生成(CD34),增殖活性(MIB-1)以及p53和MDR(P-糖蛋白(Pgp))的表达;克隆JSB-1, C494和MRK16)。对免疫反应细胞的定量和半定量评分以及回顾性获得的临床病理变量进行统计分析。化学疗法降低了截肢率(P = .00002)。 48%的原发性诊断活检中Pgp过表达(得分≥2),并且高Pgp与术后标本中的高Pgp相关(P = .003)。相比之下,没有公开这样的关联来估计血管生成(P = .64)和p53(P> .32),而化疗后标本中的MIB-1指数降低了(P = .02)。 ,疾病特异性生存率为47%,接受术前化疗的患者增加至54%。统计分析显示,预后仅受患者年龄和骨肉瘤类型的影响。所研究的一系列患者已在化疗时代之前记录下来,相当出色的存活率以及对血管生成,增殖,p53和Pgp表达的估计,并未显示出足够的功效来预测治疗反应或存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号